Pharmaceuticals
Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans
Yvelise Barrios, MD, PhD, Immunologist and leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behindCoviDTH, joins BioVaxys as scientific adviser VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Aug. 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (C...
2021-08-03 20:00
6109
Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor
BEIJING, Aug. 3, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) today announced the first patient was dosed in a Phase I/II clinical trial of KRAS G12C inhibitor JAB-21822 inChina. JAB-21822 is Jacobio's innovative in-house small molecule anti-cancer drug, which is designed to target t...
2021-08-03 09:00
4666
Insilico Medicine and Westlake Pharma Announce Cooperation Relationship on Accelerating the Innovative Drugs R&D for Novel Coronavirus
HANGZHOU, China, Aug. 3, 2021 /PRNewswire/ -- Insilico Medicine and Westlake
Pharma announced a strategic partnership to jointly develop innovative
small-molecule drugs for Novel Coronavirus (COVID-19) today.
2021-08-03 08:00
35816
SI Group Ranks in the Top 5 Percent for Global Corporate Social Responsibility
Company Awarded Gold Rating by EcoVadis for its Sustainability Commitment SCHENECTADY, N.Y., Aug. 2, 2021 /PRNewswire/ -- SI Group, a global leader in the innovative technology of performance additives, process solutions, active pharmaceutical ingredients, and chemical intermediates, has received...
2021-08-02 22:33
3614
Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
TIBSOVO is the first targeted therapy to show improved event-free survival and overall survival in combination with azacitidine compared to azacitidine monotherapy. Safety profile consistent with previously published data in patients with IDH1-mutated acute myeloid leukemia. The study recently ...
2021-08-02 14:00
3319
Luye Pharma Enters Distribution Agreement with Zuellig Pharma for Seroquel and Seroquel XR in Malaysia and Brunei, Strengthening Business Presence in Asia Pacific and Improving Access to Evidence-Based Medical Treatments for Mental Health
SUBANG JAYA, Malaysia, Aug. 2, 2021 /PRNewswire/ -- Luye Pharma Group today announced that it has entered into an agreement with Zuellig Pharma, a leading healthcare service group inAsia, under which the company grants Zuellig Pharma exclusive rights to distribute its central nervous system drugs...
2021-08-02 10:25
5511
Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma
SEOUL, South Korea and SHANGHAI and HONG KONG, Aug. 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics i...
2021-08-02 07:29
6384
EC Healthcare and Prenetics Form Strategic Partnership to Pioneer the Future of Medicine
HONG KONG, July 30, 2021 /PRNewswire/ -- EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group inHong Kong, announces that the Group signed a memorandum of understanding with Prenetics Limit...
2021-07-30 15:33
10702
EDM Council Report Uncovers Major Evolution in Data Management Practices within Pharma / Life Sciences
NEW YORK, and AACHEN, Germany, July 29, 2021 /PRNewswire/ -- EDM Council, the cross-industry trade association for data management and analytics, along with OSTHUS and Strategy&, PwC's global strategy consulting business, have released the 2021 EDM Council Global Data Management Benchmark Surve...
2021-07-29 21:10
4082
Everest Medicines Receives Pediatric and Rare Severe Disease Priority Review Designation from Taiwan FDA for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
SHANGHAI, July 29, 2021 /PRNewswire/ -- Everest Medicines
2021-07-29 18:41
5306
Exyte Empowers the Biopharmaceutical Industry: First ExyCell(R) Facility Launched in Shanghai
STUTTGART, Germany and BERGISCH GLADBACH, Germany, July 29, 2021 /PRNewswire/ -- Exyte has successfully completed the construction of the first ExyCell® facility inChina, the CliniMACS Cell Factory® of Miltenyi Biotec, a global provider of integrated solutions for Advanced Therapy Medical Products...
2021-07-29 16:25
3762
Transcenta Announces Orphan Drug Designation Granted to TST001 for Treatment of Gastric and Gastroesophageal Junction
SUZHOU, China, July 29, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the U.S. Food and Drug Administrat...
2021-07-29 07:46
2766
Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325
SUZHOU, China, and ROCKVILLE, Md., July 29, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its global licensee, UNITY Biotechnology, In...
2021-07-29 07:40
4906
Fortacin™ Receives Extremely Encouraging Assessment in US Market Research Analysis
HONG KONG, July 28, 2021 /PRNewswire/ -- Endurance RP Limited ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) is pleased to announce that Fortacin™, a European,Hong Kong andMacau approved treatment for PE receives a detailed market ass...
2021-07-28 20:05
9080
Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia
SHANGHAI, July 28, 2021 /PRNewswire/ -- Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced the initiation of a Phase 1a clinical trial evaluating ECC0509, an oral inhibitor of semicarbazide-sensitive...
2021-07-28 17:13
2859
India-based MedTel receives investment term sheet from Catalist-listed Metal Component Engineering (MCE, SGX:5DX)
SINGAPORE, July 28, 2021 /PRNewswire/ -- Catalist-listed Metal Component Engineering Limited ("MCE") is pleased to announce that it has, through its subsidiary, Metal Precision Services Pte Ltd, entered into a term sheet to take an equity stake in MedTel Healthcare Private Limited ("MedTel"). MCE...
2021-07-28 11:36
12093
More than Half of Singaporeans Unaware of Link between Viral Hepatitis and Liver Failure: Survey
* New survey demonstrates general apathy among Singaporeans towards liver health, particularly among those aged 25 and below, despite high rates of liver cancer and failure in the country * Hepatitis B causes 60-70% of total number of liver cancer cases in the country[1]; liver cancer known ...
2021-07-28 11:00
2007
Gilead Sciences Announces Launch of Asia Pacific ALL4LIVER Grant 2021
– Biennial Grant Program Supports Community Projects Focused on Improving Education About Liver Health inSingapore and 10 Other Countries and Territories– – Inaugural Cycle of the Grant will Focus on Hepatitis B Awareness Initiatives – SINGAPORE, July 28, 2021 /PRNewswire/ -- Gilead Sciences, I...
2021-07-28 11:00
4105
Ascletis Announces Completion of 149 Patient Enrollment and Positive Interim Results of Phase IIb Chronic Hepatitis B Study in China for its Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)
* HBsAg reduction was observed in the 1 mg/kg ASC22 once every two weeks plus nucleos(t)ide analogs group with greater HBsAg reduction observed in patients with HBsAg ≤ 500 IU/mL at baseline while no HBsAg reduction was observed for the placebo plus nucleos(t)ide analogs group * Receptor oc...
2021-07-28 08:30
3654
VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant
* New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE™ nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure * SPL7013, the antiviral agent in V...
2021-07-27 19:53
5683
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 309 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 281 media titles]
2026-05-20 09:15AIMX Singapore 2026 Anchors Strategic Relationship with TechInnovation and AI Gravity
[Picked up by 279 media titles]
2026-05-19 14:00
Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
7854
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
7666
IBM and U.S. Department of Commerce Announce America's First Purpose-Built Quantum Foundry, Supported by Proposed $1 Billion CHIPS Award
2026-05-21 20:11
6796
/C O R R E C T I O N -- The American Chamber of Commerce in Singapore (AmChamSG)/
2026-05-21 12:14
6713
